Table 3.
Outcomes by Baseline NT‐proBNP
| Unadjusted | Adjusted | |||
|---|---|---|---|---|
| Clinical Outcome | OR for BL NT‐proBNP (95% CI) | P Value | OR for BL NT‐proBNP (95% CI) | P Value |
| Short‐term outcomes | ||||
| 30‐d death or HF‐rehosp.a | 1.19 (1.02, 1.39) | 0.027 | 1.12 (0.93, 1.34) | 0.25 |
| 30‐d death or all‐cause‐rehosp.a | 1.17 (1.03, 1.33) | 0.015 | 1.07 (0.93, 1.25) | 0.35 |
| Worsening renal functionb | 1.02 (0.86, 1.22) | 0.79 | 1.13 (0.93, 1.38) | 0.22 |
| Long‐term outcomes | HR for BL NT‐proBNP (95% CI) | P Value | HR for BL NT‐proBNP (95% CI) | P Value |
|---|---|---|---|---|
| 180‐d deatha | 1.58 (1.36, 1.83) | <0.001 | 1.40 (1.16, 1.71) | <0.001 |
Analyses adjusted for prespecified variables found to be correlated with outcomes. Hazard ratio (HR) and odds ratio (OR) estimate the change in risk associated with doubling of the baseline value based on a base‐2 logarithm model. BL indicates baseline; CI, confidence interval; HF, heart failure; NT‐proBNP, N‐terminal‐pro‐b‐type natriuretic peptide; rehosp., rehospitalization.
Adjusted for region (North America or other), age, blood urea nitrogen (BUN), serum creatinine, serum sodium, chronic obstructive pulmonary disease, cerebrovascular disease, depression, dyspnea, systolic blood pressure, elevated jugular venous pulsation at baseline, randomized treatment assignment, and heart failure hospitalization within 1 year.
Adjusted for randomized treatment assignment, BUN, systolic and diastolic blood pressures, and weight gain.